While ICD therapy has consistently been shown to decrease mortality in patients with prior cardiac arrest and those with risk factors for life threatening ventricular arrhythmias, ICD shocks have also been associated with increased anxiety and poor long term prognosis.2,3 Therefore, much of the industry emphasis over the past 20 years has been placed on reducing both inappropriate and unnecessary shocks – those delivered for reasons other than life-threatening arrhythmias.
AVOIDING SHOCKS IS IMPORTANT
Eliminating these inappropriate and unnecessary shocks may enable:
- Reduced pain and anxiety associated with ICD therapy and increase patient acceptance of the therapy2
- Reduce the financial burden of managing patients who receive ICD shocks and improve their Quality of Life2
- Improved long term prognosis and, potentially survival, of ICD recipients3
In the end, our goal is to shock only to save a life.
SHOCKS INCREASE HEALTHCARE UTILIZATION
Inappropriate and unnecessary shocks can increase healthcare expenditures. Globally, 199,000 patients receive a new or replacement ICD each year.4
Based on reported shock rates, approximately 54,000 shocks are delivered each year and the estimated annual cost of managing patients who receive these shocks is $112 million.
1 Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single and dual/triple chamber ICDs using a novel suite of detection algorithms: PainFree SST Trial Primary Results. Heart Rhythm. 2015;12:926-36.
2 Wathen MS, DeGroot PJ, Sweeney MO, et al, for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. October 26, 2004;110(17):2591-2596.
3 Sweeney MO, et al. Differences in effects of electrical therapy type on health care utilization in the MVP ICD Trial. Presented at HRS 2010.
4 Millennium Research Group, Market Research Report on Global Markets for Cardiac Rhythm Management Devices, July 2012.